GlassScriptPhysician profile
Susan Daly
NPI 1205418498
$7,677.98
in general payments reported to CMS, 2019-2025
20 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,124 · 2022: $3,369 · 2023: $1,951 · 2024: $736 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,184.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,866.69 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $1,151.49 | 2021-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,136.62 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $791.84 | 2021-2023 | Rexulti |
| Lundbeck LLC | $632.79 | 2021-2023 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $556.03 | 2021-2023 | Austedo |
| Abbvie INC. | $421.93 | 2022-2025 | |
| Corium, LLC | $224.42 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $158.12 | 2024 | Auvelity |
| Almatica Pharma LLC | $132.27 | 2022-2023 | Sertraline Hcl, Loreev Xr |
| Neurocrine Biosciences, INC. | $120.19 | 2022-2023 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $89.90 | 2024 | Cobenfy |
| Bausch Health US, LLC | $76.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $74.75 | 2023 | Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $63.77 | 2022-2023 | Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $48.72 | 2022-2023 | Dyanavel Xr |
| Indivior INC. | $44.43 | 2021-2023 | Sublocade |
| Merck Sharp & Dohme LLC | $39.04 | 2021-2023 | Belsomra |
| Ironshore Pharmaceuticals INC. | $24.53 | 2023 | Jornay Pm |
| Neos Therapeutics, LP | $24.22 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.